Medicare Part D price protection may be on its last legs for seniors.

That's according to the Center for Retirement Research at Boston College, which singled out research from the Kaiser Family Foundation on price spikes for specialty drugs as a threat to seniors' ability to manage their out-of-pocket drug spending.

Price hikes on drugs were a major source of headlines during 2015, with former Turing Pharmaceuticals CEO Martin Shkreli coming in for a firestorm of criticism after his company increased the price on Daraprim, a drug used by cancer and AIDS patients by 5,000 percent.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.